REAADS Anti-Cardiolipin IgG/IgM Semi-Quantitative Test Kit, Model 023-001
510(k) K022992
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK022992 | Date25 Sep 2002 | StatusActive |
Recalls
No FDA recalls found in the data synced 6 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- MID
- Device Class
- Class II
- Regulation
- 21 CFR Part 866.5660
- Advisory Committee
- Immunology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 19 Sep 2026
The REAADS Anti-Cardiolipin IgG/IgM Semi-Quantitative Test Kit is an enzyme-linked immunosorbent assay (ELISA) system designed for the immunological detection and semi-quantitative measurement of IgG and IgM anti-cardiolipin antibodies in human serum or plasma. This device falls under the category of immunological test systems, specifically for identifying markers associated with autoimmune conditions.
This test kit is intended for in vitro diagnostic use in clinical laboratory settings. It is supplied as a 96-well format for batch testing and requires no sterilisation beyond standard laboratory practices. The device is classified as Class II under FDA regulations and holds a 510(k) clearance, ensuring compliance with immunology diagnostic standards. Storage and handling follow standard in vitro diagnostic protocols.